Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14226494 | 0.83 | GAA (0.40) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL9683285 | 0.82 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28867969 | 0.82 | TSHR (0.30) | TSHR | |
| SCHEMBL15447195 | 0.81 | CYP1A2 (0.40) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL26711236 | 0.81 | GAA (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7846482 | 0.81 | GAA (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL232993 | 0.81 | GAA (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11059357 | 0.80 | ALDH1A1 (0.41) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11140647 | 0.78 | GAA (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11455507 | 0.78 | ALDH1A1 (0.41) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228680-A1 | METHOD FOR PREPARING POLYMER, AND OBTAINED POLYMER | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| EP-4332135-A1 | METHOD FOR PREPARING POLYMER, AND OBTAINED POLYMER | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2024-03-06 | — | — | EP | disclosed |
| EP-4225765-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-115246901-B | Preparation method of olefin-unsaturated carboxylic ester copolymer and copolymer | 中国石油化工股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116601158-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-115246900-B | Polymer preparation method and polymer | 中国石油化工股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-115246902-B | Method for preparing copolymer, copolymer and application | 中国石油化工股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-115260356-B | Method for preparing olefin-unsaturated carboxylic ester copolymer, olefin-unsaturated carboxylic ester copolymer and application | 中国石油化工股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116217759-A | Coordination precipitation polymerization method for olefin polymerization and obtained polyolefin | 中国石油化工股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116199806-A | Coordination precipitation polymerization method for olefin polymerization and obtained polyolefin | 中国石油化工股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2022227933-A1 | METHOD FOR PREPARING POLYMER, AND OBTAINED POLYMER | 中国石油化工股份有限公司 | 2022-11-03 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-2331552-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2331552-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2331552-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010036551-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036551-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | GAA 175/4885MGAM 2131/4885SI 895/4885 |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GAA 1041/4885MGAM 1758/4885SI 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.